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Introduction {#sec001}
============

The mammalian [Nu]{.ul}cleosome [R]{.ul}emodeling and Histone [D]{.ul}eacetylase (NuRD/Mi-2) complex is an ATP-dependent chromatin-remodeling complex that can transiently displace nucleosomes within gene regulatory regions and thereby impact transcription \[[@pone.0235799.ref001]\]. NuRD complexes are composed of multiple proteins, many of which have varying isoforms that can contribute to differential NuRD assembly in specific cell types and tissues \[[@pone.0235799.ref002], [@pone.0235799.ref003]\]. Among these proteins, the [C]{.ul}hromodomain-[H]{.ul}elicase-[D]{.ul}NA-Binding ATPases CHD3 and CHD4 (also called Mi-2α and Mi-2β) are critical for NuRD activity because they provide the energy and helicase function required for chromatin remodeling \[[@pone.0235799.ref004]\]. Recent evidence suggests that CHD3 and CHD4 are mutually exclusive within NuRD complexes, despite the fact that they are co-expressed in various cell types \[[@pone.0235799.ref005], [@pone.0235799.ref006]\].

NuRD complexes play various roles in developmental and cellular differentiation processes, such as suppression of embryonic stem cell pluripotency, maintenance and lineage commitment of hematopoietic stem cells, maintenance of nephron progenitors in the kidney, peripheral nerve myelination, and cortical development in the brain \[[@pone.0235799.ref006]--[@pone.0235799.ref010]\]. Many of these and additional discoveries resulted from studies focused on genetic deletion of a single NuRD component or a NuRD-interacting cofactor \[[@pone.0235799.ref011]\]. A *Chd4*-flox allele generated by Katia Georgopoulos' lab \[[@pone.0235799.ref012]\] has been particularly useful for defining the function of CHD4-NuRD complexes in specific cell types in vivo.

Our lab has a long-standing interest in the role of chromatin-remodeling enzymes in vascular development. We genetically delete chromatin-remodeling enzymes like CHD4 in murine embryonic endothelial cells in order to determine the impact on developing blood vessels and to identify target genes that require tight transcriptional regulation during vascular development \[[@pone.0235799.ref013]\]. We previously reported that CHD4 is required for maintenance of vascular integrity at midgestation and during liver development \[[@pone.0235799.ref014]--[@pone.0235799.ref016]\]. We also described how CHD4 counteracts the activity of the chromatin-remodeling enzyme BRG1 to regulate the Wnt signaling pathway in developing blood vessels \[[@pone.0235799.ref017]\]. Together these studies demonstrate that CHD4 plays critical roles in embryonic vascular development and maintenance, presumably through its participation in NuRD-related transcriptional regulation events in endothelial cells.

Because of the interesting and varied vascular phenotypes we saw associated with *Chd4* deletion in developing vasculature, we wondered what role the alternative NuRD ATPase CHD3 might play in embryonic blood vessels. No knockout or conditional allele of *Chd3* currently exists for genetic deletion studies in mice. Instead, one report describes electroporating shRNAs against CHD3 into embryonic mouse brains in order to inhibit CHD3 in vivo \[[@pone.0235799.ref006]\]. In this study we sought to analyze CHD3 during vascular development by generating a *Chd3*-flox allele and deleting the gene in developing endothelial cells. Although we found no obvious roles for CHD3 in early vascular development, global deletion of the gene resulted in partial embryonic lethality. Our genetic crosses and expression data from adult mouse tissues---along with recent reports about CHD3 roles in neural development---suggest that CHD3 may contribute to viable embryonic brain development.

Materials and methods {#sec002}
=====================

Mice {#sec003}
----

All animal use protocols were approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee (protocol \#20--15), and all efforts were made to minimize animal suffering. Animals were originally described and obtained from the following sources: *Chd3*-flox, generated by Cyagen Biosciences as described in this paper; *Chd4*-flox \[[@pone.0235799.ref012]\], gift of Dr. Katia Georgopoulos (Harvard Medical School); *Tie2-Cre* \[[@pone.0235799.ref018]\], The Jackson Laboratory \#008863; *Sox2-Cre* \[[@pone.0235799.ref019]\], The Jackson Laboratory \#008454; and FLPe \[[@pone.0235799.ref020]\], The Jackson Laboratory \#005703. Timed matings were assessed by checking daily for a copulation plug; noon on the day of plug detection was designated as embryonic day 0.5 (E0.5). Embryos and yolk sacs were dissected from maternal tissue, and yolk sacs were digested for genotyping assays. Gross embryonic images were obtained with a Nikon SMZ800 stereomicroscope and Nikon DS-Fi1 camera and monitor. Genotyping primers and conditions are described in [Table 1](#pone.0235799.t001){ref-type="table"}.

10.1371/journal.pone.0235799.t001

###### Genotyping primers and conditions.

![](pone.0235799.t001){#pone.0235799.t001g}

  Allele                                        Genotyping Primers                              Annealing Temperature   Amplicon Size
  --------------------------------------------- ----------------------------------------------- ----------------------- ------------------
  *Chd3*-flox                                   Forward (F): `5’-GGGTGGAGGTGGAAAGTGTA-3’`       55°C                    Wildtype: 152 bp
  Reverse (R1): `5’-AGAGGACAGGTCACAGGACAA-3’`   Floxed: 213 bp                                                          
  *Chd3*^*Δ*^                                   Forward (F): `5’-GGGTGGAGGTGGAAAGTGTA-3’`       59°C                    \~230 bp
  Reverse (R2): `5’-GGCACAGCTTCTCTGAGACC-3’`                                                                            
  *Chd4*-flox                                   Forward: `5’-TCCAGAAGAAGACGGCAGAT-3’`           55°C                    Wildtype: 278 bp
  Reverse: `5’- CTGGTCATAGGGCAGGTCTC-3’`        Floxed: 400 bp                                                          
  *Chd4*^*Δ*^                                   Forward: `5’-TCCAGAAGAAGACGGCAGAT-3’`           59°C                    \~350 bp
  Reverse: `5’-CAGCGTGTCAGAGTTTGCAT-3’`                                                                                 
  *Tie2-Cre*                                    Forward: `5’-GGGAAGTCGCAAAGTTGTGAGTTG-3’`       60°C                    533 bp
  Reverse: `5’-TCCATGAGTGAACGAACCTGGTCG-3’`                                                                             
  *Sox2-Cre*                                    Forward: `5’-TGCAACGAGTGATGAGGTTC-3’`           58°C                    528 bp
  Reverse: `5’-ATTCTCCCACCGTCAGTACG-3’`                                                                                 
  *FLPe*                                        Forward: `5’-AGTAGTGATCAGGTATTGCTGTTATCTG-3’`   60°C                    100 bp
  Reverse: `5’-GACTAATGTTGTGGGAAATTGGAG-3’`                                                                             

Immunoblotting {#sec004}
--------------

Total protein harvested from eight-week old mouse tissues was quantified with the Pierce BCA Protein Assay Kit (Thermo Scientific). Protein (20--30μg) was fractionated on a 9% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane for immunoblotting with one of two antibodies against CHD3 (1:2000; BD Biosciences; Cat. \#611847; RRID: AB_399327; or 1:1000; Abcam; Cat. \#ab109195; RRID: AB_10862514) and GAPDH (1:5000; Sigma; Cat. \#9545; RRID: AB_796208). Horseradish peroxidase-conjugated secondary antibodies and SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) were used for detection. Imaging was performed on a Fluorchem HD2 (Alpha Innotech) and scanned with an imageRUNNER 3225 (Canon).

Statistics {#sec005}
----------

Statistical methodology is described in the table legends.

Results {#sec006}
=======

Generation of a *Chd3*-flox allele {#sec007}
----------------------------------

In order to generate a *Chd3*-flox allele to facilitate conditional deletion of the chromatin-remodeling enzyme in vivo, we contracted with Cyagen Biosciences to design a targeting vector for homologous recombination in embryonic stem (ES) cells ([Fig 1A--1D](#pone.0235799.g001){ref-type="fig"}). We chose to flank exons 13 through 20 of the murine *Chd3* gene with loxP sites, since the CHD3 ATPase helicase---which mediates the critical function of the protein \[[@pone.0235799.ref021]\]---is encoded in this region. Deletion of these exons via Cre-mediated recombination was predicted to result in loss of function of the *Chd3* gene by generating a frameshift mutation. Homologous recombination of the targeting vector in ES cells was confirmed by Cyagen Biosciences by Southern blotting prior to blastocyst injection. Targeting and excision events were confirmed by PCR in F1 and subsequent generations of mice ([Fig 1E](#pone.0235799.g001){ref-type="fig"}).

![Generation of a conditional murine *Chd3* knockout allele.\
The *Chd3*-flox allele was generated using homologous recombination of a targeting vector in C57Bl/6 embryonic stem cells. (A): The wildtype murine *Chd3* allele contains 40 exons and resides on chromosome 11. (B): The targeting vector incorporated a 5' LoxP site (red triangle) inserted between exons 12 and 13 and a 3' LoxP site inserted between exons 20 and 21 of the wildtype *Chd3* allele. In addition, a neomycin resistance (Neo) cassette flanked by Frt sites (green bars) was inserted immediately upstream of the 3' LoxP site for positive selection of the integrated targeting vector. (C): The Neo cassette was removed by crossing mice carrying the targeted allele to FLPe-recombinase mice, leaving a single Frt site upstream of the 3' LoxP site in the *Chd3-flox* allele after recombination. Genotyping primers are indicated below the allele. (D): After crossing mice carrying the *Chd3-flox* allele to a line carrying a Cre recombinase, exons 13--20 were deleted (*Chd3*^*Δ*^). (E): The indicated mice were genotyped by PCR using the primers shown in parentheses and diagrammed in (C) to demonstrate targeting and Cre-mediated excision of the *Chd3*-flox allele. PCR products were run on a 2% agarose gel. See [Table 1](#pone.0235799.t001){ref-type="table"} for primer sequences and predicted amplicon sizes.](pone.0235799.g001){#pone.0235799.g001}

CHD3 is not essential for embryonic vascular development or for adult vascular maintenance {#sec008}
------------------------------------------------------------------------------------------

In order to determine whether CHD3 plays a critical role in vascular development or maintenance, we next crossed the *Chd3*-flox allele onto a transgenic *Tie2-Cre* recombinase line that is expressed in embryonic endothelial and hematopoietic cells \[[@pone.0235799.ref018]\]. We found that *Chd3*^*fl/fl*^*;Tie2-Cre*^*+*^ mice (hereafter, *Chd3*^*ECKO*^ for *Chd3*-[e]{.ul}ndothelial [c]{.ul}ell [k]{.ul}nock[o]{.ul}ut) were born in expected numbers and survived past weaning and into adulthood without obvious abnormalities ([Table 2](#pone.0235799.t002){ref-type="table"}).

10.1371/journal.pone.0235799.t002

###### Live offspring at weaning from *Chd3*^*fl/+*^ X *Chd3*^*fl/+*^*;Tie2-Cre*^*+*^ crosses[^a^](#t002fn002){ref-type="table-fn"}.

![](pone.0235799.t002){#pone.0235799.t002g}

  Genotype                                           Observed Offspring[^b^](#t002fn003){ref-type="table-fn"}   Expected Offspring
  -------------------------------------------------- ---------------------------------------------------------- --------------------
  *Chd3*^*+/+*^                                      6                                                          9.5
  *Chd3*^*fl/+*^                                     29                                                         19
  *Chd3*^*fl/fl*^                                    8                                                          9.5
  *Chd3*^*+/+*^*;Tie2-Cre*^*+*^                      9                                                          9.5
  *Chd3*^*fl/+*^*;Tie2-Cre*^*+*^                     15                                                         19
  *Chd3*^*fl/fl*^*;Tie2-Cre*^*+*^ (*Chd3*^*ECKO*^)   9                                                          9.5

***Chd3***^***fl/fl***^***;Tie2-Cre***^***+***^ **(*Chd3***^***ECKO***^**) mice survive development.** 76 mouse pups generated from matings between *Chd3*^*fl/+*^*;Tie2-Cre*^*+*^ males and *Chd3*^*fl/+*^ females were genotyped at weaning (\~19 days). No lethal embryonic vascular anomalies are associated with the *Chd3*^*ECKO*^ genotype, since the numbers of *Chd3*^*fl/fl*^*;Tie2-Cre*^*+*^ progeny observed approximate those expected.

^a^11 litters generated from 8 *Chd3*^*fl/+*^ females and 5 *Chd3*^*fl/+*^*;Tie2-Cre*^*+*^ males were genotyped.

^b^χ^2^(5~dof~) = 7.68, 0.5\>*P*\>0.1.

Although our genetic crosses indicated that no lethal vascular or hematopoietic abnormalities arose from *Chd3* deletion with the *Tie2-Cre* recombinase, we visually analyzed *Chd3*^*ECKO*^ embryos at midgestation, since that is the developmental stage at which we had previously observed significant vascular phenotypes in *Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^ (hereafter *Chd4*^*ECKO*^) embryos \[[@pone.0235799.ref014], [@pone.0235799.ref015]\]. Specifically, we dissected *Chd3*^*ECKO*^ and *Chd4*^*ECKO*^ embryos at E11.5; while the *Chd4*^*ECKO*^ embryos displayed lethal vascular rupture and hemorrhage, as we previously described, the *Chd3*^*ECKO*^ embryos were indistinguishable from control littermates ([Fig 2A--2C](#pone.0235799.g002){ref-type="fig"}).

![*Chd3*^*ECKO*^ embryos are alive and display normal gross morphology at E11.5.\
Photographs of representative E11.5 littermate embryos are shown. Each embryo was pronounced alive or dead at the time of dissection based on the presence or absence of a visible heartbeat. Numbers in the bottom left corner of each picture report the embryos resembling that picture/total embryos of each genotype dissected at E11.5. (A): Control = *Tie2-Cre*^*-*^ (B): *Chd3*^*ECKO*^ *= Chd3*^*fl/fl*^*;Tie2-Cre*^*+*^ (C): *Chd4*^*ECKO*^ *= Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^ (D): *Chd3/4*^*ECKO*^ *= Chd3*^*fl/fl*^*;Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^.](pone.0235799.g002){#pone.0235799.g002}

Vascular phenotypes in *Chd3*^*fl/fl*^*;Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^ (*Chd3/4*^*ECKO*^) embryos resemble those seen in *Chd4*^*ECKO*^ mutants {#sec009}
-----------------------------------------------------------------------------------------------------------------------------------------------

Because we have reported that chromatin-remodeling enzymes can co-regulate the same target genes or signaling pathways in developing blood vessels \[[@pone.0235799.ref017]\], we next sought to determine whether CHD3 plays a cooperative or antagonistic role with CHD4 during embryonic vascular development. Specifically, we generated embryos deficient for both endothelial *Chd3* and *Chd4* (*Chd3*^*fl/fl*^*;Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^, hereafter *Chd3/4*^*ECKO*^) to determine whether the vascular phenotype was different from that seen in littermate *Chd4*^*ECKO*^ embryos. We observed a comparable onset of lethality in *Chd3/4*^*ECKO*^ and *Chd4*^*ECKO*^ embryos between E10.5--11.5 ([Table 3](#pone.0235799.t003){ref-type="table"} and [Fig 2D](#pone.0235799.g002){ref-type="fig"}). Therefore, endothelial and hematopoietic cell deletion of *Chd3* did not rescue lethal *Chd4*^*ECKO*^ vascular phenotypes at midgestation. In addition, we assessed *Chd3/4*^*ECKO*^ embryos at E10.5---one day prior to the vascular rupture seen in *Chd4*^*ECKO*^ embryos---and saw no indication of vascular abnormalities ([Fig 3](#pone.0235799.g003){ref-type="fig"}). Therefore, *Tie2-Cre*-mediated deletion of *Chd3* did not exacerbate the timing or severity of *Chd4*^*ECKO*^ vascular phenotypes. Altogether, these genetic data indicate that CHD4 plays a more consequential role than does CHD3 in NuRD-mediated chromatin-remodeling activities during early vascular development.

![*Chd3/4*^*ECKO*^ embryos display normal gross morphology at E10.5.\
Photographs of representative live E10.5 littermate embryos are shown. Numbers in the bottom left corner of each picture report live embryos/total embryos of each genotype dissected at E10.5. (A): Control = *Tie2-Cre*^*-*^ (B): *Chd3*^*ECKO*^ *= Chd3*^*fl/fl*^*;Tie2-Cre*^*+*^ (C): *Chd4*^*ECKO*^ *= Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^ (D): *Chd3/4*^*ECKO*^ *= Chd3*^*fl/fl*^*;Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^.](pone.0235799.g003){#pone.0235799.g003}

10.1371/journal.pone.0235799.t003

###### Total numbers of embryos genotyped (and % dead) at midgestation.

![](pone.0235799.t003){#pone.0235799.t003g}

  Genotype                                 E10.5      E11.5
  ---------------------------------------- ---------- ----------
  Control                                  74 (3%)    35 (14%)
  *Chd3*^*ECHet*^ and/or *Chd4*^*ECHet*^   40 (1%)    19 (0%)
  *Chd3*^*ECKO*^                           26 (12%)   2 (0%)
  *Chd4*^*ECKO*^                           32 (6%)    6 (83%)
  *Chd3/4*^*ECKO*^                         8 (12%)    2 (100%)

**The majority of *Chd3/4***^***ECKO***^ **embryos die between E10.5--11.5.** Embryos were dissected at E10.5 or E11.5 from various matings that produce the following genotypes: Control (*Tie2-Cre*^*-*^), *Chd3*^*ECHet*^ (*Chd3*^*fl/+*^*;Tie2-Cre*^*+*^), *Chd4*^*ECHet*^ (*Chd4*^*fl/+*^*;Tie2-Cre*^*+*^), *Chd3*^*ECKO*^ (*Chd3*^*fl/fl*^*;Tie2-Cre*^*+*^), *Chd4*^*ECKO*^ (*Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^), or *Chd3/4*^*ECKO*^ (*Chd3*^*fl/fl*^*;Chd4*^*fl/fl*^*;Tie2-Cre*^*+*^). All embryos were deemed "alive" or "dead" at the time of dissection based on the presence or absence of a visible heartbeat. The death of most *Chd4*^*ECKO*^ embryos between E10.5--11.5 is consistent with our previous reports \[[@pone.0235799.ref014], [@pone.0235799.ref015]\].

Global deletion of *Chd3* results in partial embryonic lethality {#sec010}
----------------------------------------------------------------

Since we saw no visible phenotypes associated with deletion of *Chd3* in blood vessel endothelial cells and hematopoietic cells, we next sought to determine the consequence of global excision of our *Chd3*-flox allele. We crossed the *Chd3*-flox line onto a *Sox2-Cre*^*+*^ recombinase line that is expressed in all embryonic cells starting at the epiblast stage of development \[[@pone.0235799.ref019]\]. We found an underrepresentation of *Chd3*^*fl/fl*^*;Sox2-Cre*^*+*^ (hereafter called *Chd3*^***Δ/Δ***^*;Sox2-Cre*^*+*^ or *Chd3*-knockout) mice at weaning ([Table 4](#pone.0235799.t004){ref-type="table"}). Likewise, matings between *Chd3*^*Δ/fl*^ (*Chd3*-heterozygous) mice confirmed partial lethality of *Chd3*^***Δ/Δ***^ (*Chd3*-knockout) mice ([Table 5](#pone.0235799.t005){ref-type="table"}). Because we did not observe noticeable lethality of pups between birth and weaning when performing these crosses, we believe that *Chd3*-knockout embryos died before birth.

10.1371/journal.pone.0235799.t004

###### Live offspring at weaning from *Chd3*^*fl/+*^*;Sox2-Cre*^*+*^ (*Chd3*^*Δ/+*^*;Sox2-Cre*^*+*^) X *Chd3*^*fl/+*^ crosses[^a^](#t004fn002){ref-type="table-fn"}.

![](pone.0235799.t004){#pone.0235799.t004g}

  Genotype                            Observed Offspring[^b^](#t004fn003){ref-type="table-fn"}   Expected Offspring
  ----------------------------------- ---------------------------------------------------------- --------------------
  *Chd3*^*+/+*^                       21                                                         25.375
  *Chd3*^*fl/+*^                      22                                                         25.375
  *Chd3*^*Δ/+*^                       26                                                         25.375
  *Chd3*^*Δ/fl*^                      35                                                         25.375
  *Chd3*^*+/+*^*;Sox2-Cre*^*+*^       33                                                         25.375
  *Chd3*^*Δ/+*^*;Sox2-Cre*^*+*^       53                                                         50.75
  *Chd3*^***Δ/Δ***^*;Sox2-Cre*^*+*^   13                                                         25.375

***Chd3***^***Δ/Δ***^***;Sox2-Cre***^***+***^ **progeny are underrepresented in offspring from *Chd3***^***Δ/+***^***;Sox2-Cre***^***+***^ **males and *Chd3***^***fl/+***^ **females.** 203 mouse pups generated from matings between *Chd3*^*Δ/+*^*;Sox2-Cre*^*+*^ males and *Chd3*^*fl/+*^ females were genotyped at weaning (\~19 days).

^a^19 litters generated from 5 *Chd3*^*fl/+*^ females and 4 *Chd3*^*Δ/+*^*;Sox2-Cre*^*+*^ males were genotyped.

^b^χ^2^(6~dof~) = 13.30, *P*\<0.05.

10.1371/journal.pone.0235799.t005

###### Live offspring at weaning from *Chd3*^*Δ/fl*^ X *Chd3*^*Δ/fl*^ crosses[^a^](#t005fn002){ref-type="table-fn"}.

![](pone.0235799.t005){#pone.0235799.t005g}

  Genotype            Observed Offspring[^b^](#t005fn003){ref-type="table-fn"}   Expected Offspring
  ------------------- ---------------------------------------------------------- --------------------
  *Chd3*^*fl/fl*^     19                                                         15
  *Chd3*^*Δ/fl*^      35                                                         30
  *Chd3*^***Δ/Δ***^   6                                                          15

***Chd3***^***Δ/Δ***^ **progeny are underrepresented in offspring from *Chd3***^***Δ/fl***^ **matings.** 60 mouse pups generated from matings between *Chd3*^*Δ/fl*^ males and females were genotyped at weaning (\~19 days).

^a^7 litters generated from 2 *Chd3*^*Δ/fl*^ males and 2 *Chd3*^*Δ/fl*^ females were genotyped.

^b^χ^2^(2~dof~) = 7.3, *P*\<0.05.

CHD3 is predominantly expressed in adult gonads and brain tissue {#sec011}
----------------------------------------------------------------

We next surveyed CHD3 expression in adult tissues, with hopes of gaining insight into possible causes of lethality for *Chd3*^*Δ/Δ*^ animals. We harvested a variety of tissues from wildtype male and female mice and analyzed CHD3 expression by immunoblotting. We detected CHD3 protein predominantly in the brains (of both sexes), testes, and ovaries of eight-week-old mice ([Fig 4](#pone.0235799.g004){ref-type="fig"}). In order to validate the CHD3 antibodies we utilized for immunoblotting and to confirm the efficiency of *Chd3* deletion with the *Sox2-Cre* recombinase, we assessed CHD3 expression in adult littermate wildtype, *Chd3*-heterozygous (*Chd3*^*Δ/fl*^), and surviving *Chd3*-knockout (*Chd3*^*Δ/Δ*^) mice ([Fig 5](#pone.0235799.g005){ref-type="fig"}). Immunoblotting for CHD3 protein in brain tissue revealed the expected reduction of CHD3 expression in *Chd3*-heterozygous samples and absence of detectable CHD3 in *Chd3*-knockout samples. Therefore, our *Chd3*-flox allele can be excised efficiently. Moreover, our expression analyses suggest that the partial pre-weaning lethality we observe on the *Chd3*-knockout background could be due to compromised fertility or to fatal brain defects, such as the cortical abnormalities recently described when CHD3 is knocked down in developing mouse brains \[[@pone.0235799.ref006]\].

![CHD3 is predominantly expressed in the brain and gonads of adult mice.\
Representative immunoblots of tissues from a single male and female wildtype mouse are shown. GAPDH was immunoblotted as a loading control. At least three mice of each gender were analyzed with comparable results.](pone.0235799.g004){#pone.0235799.g004}

![*Chd3* is efficiently excised with the *Sox2-Cre* recombinase.\
Representative immunoblots of brains from two sets of wildtype (*Chd3*^*+/+*^), *Chd3*-heterozygous (*Chd3*^*Δ/+*^) and *Chd3*-knockout (*Chd3*^*Δ/Δ*^*;Sox2-Cre*^*+*^) male mice are shown. Four mice of each genotype were analyzed with comparable results.](pone.0235799.g005){#pone.0235799.g005}

Discussion {#sec012}
==========

This study describes the first report of a conditional allele that facilitates global and cell-specific genetic analyses of CHD3 function in murine tissues. Our data indicate that CHD3 does not play a critical role in embryonic vascular development or adult blood vessel maintenance. This finding stands in contrast to our previous work with CHD4, an alternative NuRD ATPase, which transcriptionally regulates vascular development and integrity at multiple stages of embryonic life \[[@pone.0235799.ref014]--[@pone.0235799.ref017]\]. At face value, these results indicate that CHD4-NuRD complexes are the predominant or most consequential NuRD complexes in endothelial cells and hematopoietic cells. However, it is possible that CHD3-NuRD complexes play transcriptional regulatory roles in blood vessels under challenge conditions that were not incorporated into this study, such as ischemia, hypertension, inflammation, glucotoxicity or in solid tumors. Future work with constitutive *Chd3*^*ECKO*^ and inducible *Chd3/4*^*ECKO*^ mice could address this possibility. It is also interesting to consider the contribution of a third NuRD ATPase---CHD5---toward endothelial cell transcriptional regulation. As we report in this study for CHD3, CHD5 is predominantly expressed in the mouse brain and testes \[[@pone.0235799.ref022]--[@pone.0235799.ref024]\]. Therefore, CHD5 may also play inconsequential roles in the vasculature. Nevertheless, conditional genetic deletion studies---such as those described in the present study---would be the most rigorous way to assess possible roles for CHD5-NuRD complexes in vascular development.

Even though we found no consequential roles for CHD3 in blood vessels, our study does indicate that global deletion of *Chd3* with a *Sox2-Cre* recombinase line results in partial embryonic lethality. We believe this lethality occurs during embryogenesis because we did not observe death of juvenile mice in our colony prior to weaning. Although we did not perform CHD3 expression analyses on embryonic tissues for this study, our immunoblotting assays indicate that CHD3 is predominantly expressed in the gonads and brains of adult mice, which could indicate a critical role for the protein in gametogenesis or fertility. However, we found *Chd3*-heterozygous mice (*Chd3*^*Δ/fl*^ and *Chd3*^*Δ/+*^) represented at expected numbers at weaning (Tables [4](#pone.0235799.t004){ref-type="table"} and [5](#pone.0235799.t005){ref-type="table"}), indicating that *Chd3*^***Δ***^ gametes are viable and fertile. Moreover, a recent preprint reports that CHD3 plays no significant role in testis or sperm development when our *Chd3*-flox allele is combined with a primordial germ cell-specific *Ddx4-Cre* \[[@pone.0235799.ref025]\]. Alternatively, CHD3 is expressed in embryonic mouse brain cortices as early as E15.5 and has been shown through shRNA electroporation studies to influence neuronal migration and laminar identity in late stages of embryonic cortical development \[[@pone.0235799.ref006]\]. CHD4 likewise influences cortical development, and neuronal deletion of *Chd4* with a *Nestin-Cre* results in lethality associated with microcephaly at birth \[[@pone.0235799.ref006]\]. Therefore, although the known contributions of CHD3 and CHD4 to cortical development are mechanistically different \[[@pone.0235799.ref006]\], it is possible that some of our *Chd3*-knockout embryos also die with lethal developmental brain defects.

Altogether, the *Chd3*-flox mice we have generated for this study provide opportunities for future genetic analysis of cell-specific roles for this NuRD-associated chromatin-remodeling enzyme. In particular, temporal neuronal-specific deletion of *Chd3* could further clarify its roles in embryonic and postnatal brain development, which is clinically relevant in light of the recent report that human *CHD3* mutations underlie a neurodevelopmental syndrome characterized by macrocephaly and impaired speech \[[@pone.0235799.ref021]\]. These and other *Chd3* deletion studies would complement the numerous CHD4 cell-specific studies that have already been reported and would expand our knowledge about roles for NuRD complexes in development and disease.

Supporting information {#sec013}
======================

###### 

(PDF)

###### 

Click here for additional data file.
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If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

I will look forward to receiving your revised manuscript.

Kind regards,

Edward E Schmidt

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

4\. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere:

\'The Chd3-flox allele we generated for this manuscript is briefly described in our collaborator\'s manuscript that is currently under consideration for publication (de Castro et al; Biorxiv; 2019). We do not consider this a dual publication, because generation of the Chd3-flox allele is not described in detail in the de Castro study, and the Cre-recombinase line used in that study is different than the ones used for this study. However, we cite this preprint in our discussion and therefore have uploaded it for reviewer consideration.\'

Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Review of PONE-D-20-12024, "The Chromatin-remodeling enzyme CHD3 plays a role in embryonic viability but is dispensable for early vascular development."

In this manuscript, J. Xie and colleagues generated a conditional (floxed) allele of murine CHD3, a component of the NuRD chromatin-remodeling complex. Subsequent analysis of Tie2- and Sox2-Cre-mediated deletion of the Chd3-floxed allele revealed no apparent role for CHD3 in embryonic vascular development, as was previously reported for CHD4. Interestingly, a potential requirement for CHD3 activity was suggested by Chd3-knockout mice. Global deletion of CHD3 resulted in partial lethality of mice during gestation, based on observed versus expected Chd3Δ/Δ offspring at weaning. Western blot analyses of tissue-specific expression of CHD3 revealed that CHD3 is primarily expressed in adult brain and gonads. Based on these findings, the authors conclude that CHD3 may play a role in embryonic neurodevelopment.

Comments:

1\. Although the authors showed that efficient, Cre-mediated deletion of the Chd3-flox allele and lack of CHD3 protein in adult Chd3Δ/Δ brain tissue, validation of the Chd3-flox allele would be augmented by addition of the Southern blot analysis of targeted ES cells and PCR-based analyses of Cre-mediated recombination. The authors list these analyses as "data not shown." In my opinion, this data should be included in Figure 1.

2\. In the discussion section, the authors suggest that "temporal neuronal-specific deletion of Chd3 could further clarify its roles in embryonic and postnatal brain development...," although no evidence was presented in the manuscript that CHD3 is actually expressed in developing neuronal tissue. Evidence of embryonic, tissue- and developmental stage-specific CHD3 expression would be useful in guiding future studies using Chd3-flox mice, and should be included in this manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: Review of PONE-D-20-12024 5-19-2020.pdf

###### 

Click here for additional data file.

10.1371/journal.pone.0235799.r002
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Editorial/Journal Requests:

1\. Ensure that the manuscript meets PLOS ONE's style requirements:

We have read the requirements carefully and have reformatted the manuscript and figures accordingly.

2\. "Data not shown" cannot be used in the manuscript:

The phrase "data not shown" was originally located at the end of our first "results" paragraph and referred to Southern blotting of ES cells to validate homologous recombination of the Chd3-flox targeting vector prior to blastocyst injection. This Southern blotting was performed by Cyagen Biosciences, with whom we contracted to make our Chd3-flox mice. Cyagen never sent us the Southern blot images, so we cannot include them and have therefore removed the phrase "data not shown" from the manuscript and indicated that Southern blotting was performed by Cyagen. In the same sentence, "Data not shown" also referred to PCR genotyping validation of Chd3-excision events in our mice carrying a Cre recombinase. We have now included these genotyping data in Fig 1E.

3\. Show all original uncropped and unadjusted images underlying all blot or gel results:

We have now provided all original blots and gels as Supporting Information. Please note that in collecting our original blots for Figure 4B (female mouse tissues blotted for CHD3 and GAPDH), we were unhappy with the aesthetics of the background bands on the GAPDH blot. Therefore, we re-ran the same lysates and re-probed them for CHD3 and GAPDH. The new data recapitulate the original data very closely but give a better exposure for CHD3 and a cleaner blot for GAPDH. Therefore, we have substituted these new blots for the original ones that we had submitted for Figure 4B (see uploaded \"Response to Reviewer\" document, which includes a figure showing the side-by-side original and updated blots).

 

4\. Dual publication issue:

As we reported upon submission, the Chd3-flox allele we generated for this manuscript is briefly described in our collaborator's manuscript that was reviewed by Development in April. Our collaborator (Dr. Pezza) is still revising the manuscript for resubmission to Development. Since it (1) has not yet been re-reviewed and accepted, (2) does not describe the generation of the Chd3-flox allele in detail, and (3) does not use the same Cre-recombinase lines used in this study, we do not consider this a dual publication. However, we have cited the preprint of that study in our discussion (de Castro et al; bioRxiv; 2019).

Reviewer Comments:

1\. "Although the authors showed that efficient, Cre-mediated deletion of the Chd3-flox allele and lack of CHD3 protein in adult Chd3��/� brain tissue, validation of the Chd3-flox allele would be augmented by addition of the Southern blot analysis of targeted ES cells and PCR-based analyses of Cre-mediated recombination. The authors list these as "data not shown." In my opinion, this data should be included in Figure 1."

We appreciated this suggestion and refer the Reviewer to our response to the Editor (see \#2 under "Editor/Journal Requests" above and new Fig 1E).

2\. "In the discussion section, the authors suggest that "temporal neuronal-specific deletion of Chd3 could further clarify its roles in embryonic and postnatal brain development...," although no evidence was presented in the manuscript that CHD3 is actually expressed in developing neuronal tissue. Evidence of embryonic, tissue- and developmental stage-specific CHD3 expression would be useful in guiding future studies using Chd3-flox mice, and should be included in this manuscript."

In response to this request, we have revised our Discussion (2nd to last paragraph) to cite a published report that CHD3 is expressed in embryonic mouse brain cortices as early as E15.5 (Nitarska et al, 2016, Cell Reports, 17, 1683-1698). This study also shows that electroporation of CHD3 shRNA into developing cortices compromises neuronal migration and laminar identity during development. We feel that this important citation fulfills the Reviewer's request in providing evidence for CHD3 expression in developing neuronal tissue and in demonstrating that CHD3 is functionally important for embryonic brain development.

10.1371/journal.pone.0235799.r003
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The chromatin-remodeling enzyme CHD3 plays a role in embryonic viability but is dispensable for early vascular development

PONE-D-20-12024R1

Dear Dr. Griffin,

I am pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Edward E Schmidt

Academic Editor

PLOS ONE

Additional Editor Comments (optional):
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PONE-D-20-12024R1

The chromatin-remodeling enzyme CHD3 plays a role in embryonic viability but is dispensable for early vascular development

Dear Dr. Griffin:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Edward E Schmidt

Academic Editor

PLOS ONE
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